Stockholm, 1st September 2023 - We're thrilled to announce a fantastic addition to the Alex Therapeutics family. As we continue to advance the frontiers of digital health and redefine patient-centric care, we're proud to introduce Paul Kirchmeier as our new Chief Operating Officer (COO). Paul brings a wealth of experience and a dynamic perspective to our team, succeeding Sebastian Blendow in this pivotal role.
"With over a decade of commercial and operations experience within health tech and management consulting, Paul embodies the qualities we hold dear at Alex Therapeutics. His profound insight into the healthcare industry and strategic mindset align perfectly with our commitment to pushing boundaries and enhancing patient outcomes along with our partners.”, says John Drakenberg, CEO at Alex Therapeutics.
Prior to joining Alex Therapeutics, Paul spearheaded business development & operations at NuvoAir, a groundbreaking medical device and virtual-first-care company focused on respiratory health. His role as the first commercial hire exemplifies his ability to drive growth from the earliest stages of an organization. Under his leadership, NuvoAir succeeded with multiple financing rounds, ten-folded its team size and struck deals with pharma companies, healthcare providers and payers both in the US and Europe. Earlier, Paul has worked as a Management Consultant and Executive Adviser.
"Joining Alex Therapeutics is an incredible opportunity to drive the evolution of digital health and contribute to a team that's reshaping the future of patient care. I'm excited to collaborate with the brilliant minds here and continue to build upon the foundation of excellence that's been established. Together, we'll forge new paths and create solutions that impact lives on a global scale.", says Paul Kirchmeier, COO at Alex Therapeutics.
Follow us on LinkedIn to stay updated on the latest news and developments at Alex Therapeutics.
